Tempus, Seidman Cancer Center Partner Up
Tempus and the University Hospitals Seidman Cancer Center have joined together to improve research and healthcare by making genomic data, advanced molecular analysis and clinical decision support tools available to the hospital’s researchers, physicians and healthcare providers.
As part of the new collaboration, Tempus will provide genomic and transcriptomic sequencing and analysis for ovarian and triple negative breast cancer patients. Tempus will help physicians analyze these data sets to identify patterns and potentially actionable treatments by utilizing bioinformatics and its machine learning platform.
“Over the last couple of decades, technology has transformed much of our daily lives and it is time we bring these advances into the clinic,” said Eric Lefkofsky, Co-founder and CEO of Tempus. “As we work to modernize cancer care, we are proud to bring the Tempus operating system and analytics platform to UH Seidman Cancer Center, empowering its physicians to make data-driven decisions tailored to its patients.”
UH Seidman Cancer Center, based in Cleveland, Ohio, is part of the Case Comprehensive Cancer Center at Case Western Reserve University¬ – one of 45 Comprehensive Cancer Centers in the U.S. designated by the National Cancer Institute. UH Seidman Cancer Center, which opened a 120-bed freestanding cancer hospital in 2011, is dedicated to innovative treatments and leading-edge clinical research through more than 300 ongoing studies aimed at cancer treatment and prevention.
“At UH Seidman Cancer Center, we are committed to innovation and staying on top of the latest treatment protocols and advanced decision-support tools that can assist our physicians,” said Stanton L. Gerson, Director of UH Seidman Cancer Center and Case Comprehensive Cancer Center. “We are pleased to partner with Tempus, a company that shares our commitment to innovation and bringing the power of technology into clinic.”
Tempus provides sequencing and analysis for top academic centers, hospital systems, associations, and healthcare providers.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE